Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). (2019)
Attributed to:
MICA: The Newcastle Proximity Laboratory
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1111/bjd.17036
PubMed Identifier: 30070708
Publication URI: http://europepmc.org/abstract/MED/30070708
Type: Journal Article/Review
Volume: 180
Parent Publication: The British journal of dermatology
Issue: 2
ISSN: 0007-0963